Published in Br J Cancer on January 01, 1997
Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med (2004) 2.73
Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer (2001) 1.52
Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer (2011) 1.31
From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res (2011) 1.12
Second primary malignancies after treatment for malignant lymphoma. Br J Cancer (2005) 0.97
Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys (2011) 0.92
Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol (2009) 0.88
Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis. Lung (2012) 0.84
Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med (2015) 0.77
Breast cancer after radiotherapy for Hodgkin's disease. J R Soc Med (1998) 0.75
Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst (1993) 2.44
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Leukemia following Hodgkin's disease. N Engl J Med (1990) 2.25
Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst (1995) 1.66
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol (1994) 1.25
ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer (1990) 1.17
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet (1987) 1.15
Solid cancer risk after treatment of Hodgkin's disease. Cancer (1988) 1.10
Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol (1992) 1.09
Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep (1982) 1.05
Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys (1994) 0.93
Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer (1988) 0.86
Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer (1993) 0.86
Late complications of Hodgkin's disease management. J Natl Cancer Inst Monogr (1990) 0.85
Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. Recent Results Cancer Res (1989) 0.79
Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience. Ann Hematol (1992) 0.79
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
How should cost data in pragmatic randomised trials be analysed? BMJ (2000) 6.66
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet (1999) 3.16
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial. BMJ (1998) 2.39
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
Meta-analysis of continuous outcome data from individual patients. Stat Med (2001) 2.07
A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med (2000) 2.06
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. Br J Urol (1983) 1.87
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer (1983) 1.84
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ (2007) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
The processing peptidase of yeast mitochondria: the two co-operating components MPP and PEP are structurally related. EMBO J (1988) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer (2005) 1.68
MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer (2006) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Open access follow up for inflammatory bowel disease. Would have been better to use t test than Mann-Whitney U test. BMJ (2000) 1.62
Virtual outreach: economic evaluation of joint teleconsultations for patients referred by their general practitioner for a specialist opinion. BMJ (2003) 1.62
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut (2003) 1.61
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer (2007) 1.58
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53
Localization of DNA sequences in region Xp21 of the human X chromosome: search for molecular markers close to the Duchenne muscular dystrophy locus. Am J Hum Genet (1985) 1.52
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol (2011) 1.51
Cost versus benefit in non-surgical management of patients with cancer. BMJ (1988) 1.50
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer (2008) 1.50
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol (2003) 1.49
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol (2001) 1.49
Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol (1997) 1.47
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer (2005) 1.47
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Selective avoidance of lymphatic radiotherapy in the conservative management of early breast cancer. Radiother Oncol (1992) 1.46
Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol) (2001) 1.46
Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer (2002) 1.45
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer (2003) 1.45
Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet (1989) 1.45
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol (1994) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. Eur J Cancer (1998) 1.44
Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British Nuclear Fuels. Br J Cancer (1999) 1.43
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol (1995) 1.43
Regular review: Managing testicular cancer. BMJ (2001) 1.43
Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J (1995) 1.43
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol (2005) 1.41
Myeloma and benign intracranial hypertension. BMJ (1992) 1.41
Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40
Cancer mortality and morbidity among workers at the Sellafield plant of British Nuclear Fuels. Br J Cancer (1994) 1.40
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study. Clin Oncol (R Coll Radiol) (1997) 1.39
Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer (1991) 1.39
Prevention and therapy of serous otitis media by oral decongestant: a double-blind study in pediatric practice. Pediatrics (1978) 1.39
Prothrombin mRNA is expressed by cells of the nervous system. Neuron (1991) 1.38
Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A (1991) 1.37